Australian retrospective analysis of EGFRm advanced & metastatic NSCLC patients treated with 1L or 2L Osimertinib.

Trial Identifier:	D5161R00071
Sponsor:	AstraZeneca
Collaborator:	Peter MacCallum Cancer Centre
Start Date:	July 2025
Primary Completion Date:	November 2025
Study Completion Date:	November 2025
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Australia, VIC	Melbourne, VIC, Australia, 3000

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.